LOW-VOLUME · FEMALE-LED

darifenacin Side Effects

darifenacin (also sold as Enablex) is a LOW-VOLUME FAERS extract #503 of 524 by FAERS report count. Still opens on FEMALE-LED: 76% of sex-coded reports are female (407 F / 131 M).

Data updated 2026-05-15

596
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

darifenacin reporting skew - 76% of sex-coded reports are female (407 F / 131 M). Volume band LOW-VOLUME #503 of 524 by FAERS report count; caseload SIGNAL.

Thinner FAERS extract for darifenacin (Enablex) (596 reports #503 of 524 by FAERS report count). 76% of sex-coded reports are female (407 F / 131 M). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2005–2025). Stamps SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.

PERIPHERAL SWELLING leads 91 of 596 reports

PERIPHERAL SWELLING
91
HERPES ZOSTER
83
PNEUMONIA VIRAL
79
ANAEMIA
59
ARTHRALGIA
59
ORAL PAIN
57
ARTHRITIS
56
BLOOD CHOLESTEROL INCREASED
54
LIVER FUNCTION TEST ABNORMAL
54
SYNOVITIS
54
LEUKOPENIA
53
FIBROMYALGIA
52
INFECTION
51
JOINT SWELLING
49
SOFT TISSUE DISORDER
41
DYSPNOEA
38
FATIGUE
36
FALL
34

FEMALE-LED reporters · age peak 75+

Female-led reporters (76% of sex-coded rows)

Female 407 (75%)
Male 131 (24%)
Unknown 3

Age peak 75+ (180 reports)

0-17 1 (0%)
18-44 18 (5%)
45-64 107 (29%)
65-74 63 (17%)
75+ 180 (49%)

FAERS filings rising toward 2025

2005 2025

Reactions in Death Reports

Death-mentioned subset is HEAVY here (56 reports, 9.4%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
DEATH 24
ASPHYXIA 20
ARTERIOSCLEROSIS CORONARY ARTERY 16
COMPLETED SUICIDE 7
ARTERIOSCLEROSIS 6
RESPIRATORY FAILURE 3
ACUTE KIDNEY INJURY 2
ATRIAL FIBRILLATION 2
BRADYCARDIA 2
CONDITION AGGRAVATED 2
COVID-19 2
DEMENTIA 2
FALL 2
GASTROINTESTINAL HAEMORRHAGE 2
LUNG INFILTRATION 2
PNEUMONIA 2
SEPSIS 2
TACHYCARDIA 2
ABDOMINAL DISCOMFORT 1
ABDOMINAL PAIN 1

Reactions in Hospitalization Reports

Hospitalization mid-share (174, 29.2%). Co-reported reactions:

Reaction Reports
DYSPNOEA 31
FALL 19
DRUG INTERACTION 17
URINARY TRACT INFECTION 17
PNEUMONIA 16
FATIGUE 13
ACUTE KIDNEY INJURY 12
COGNITIVE DISORDER 10
GENERAL PHYSICAL HEALTH DETERIORATION 10
CONDITION AGGRAVATED 9
CONTRAINDICATED PRODUCT ADMINISTERED 9
DYSURIA 9
HYPONATRAEMIA 9
MALAISE 9
OEDEMA PERIPHERAL 9
WEIGHT DECREASED 9
CEREBRAL HAEMORRHAGE 8
DEPRESSION 8
DIZZINESS 8
HYPOXIA 8
How to read darifenacin FAERS figures (SIGNAL · DEATH-HEAVY · HOSP-MID)

FAERS holds 596 voluntary reports linked to darifenacin (Enablex), 2005-2025. Death is listed on 56 (9.4%). Hospitalization appears on 174 (29.2%). Top co-reported indication: Product Used For Unknown Indication.

Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.

Read with darifenacin

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.